Core Structural Basis for COX-2 Selectivity in Rofecoxib
Rofecoxib (Vioxx), a selective COX-2 inhibitor, achieves selectivity through its sulfonamide group and overall diarylheterocycle scaffold. The molecule consists of a central furanone ring flanked by a 4-(methylsulfonyl)phenyl group on one side and a 3-fluorophenyl group on the other. This structure binds preferentially to the COX-2 active site due to key differences from COX-1.[1][2]
How the Sulfonamide Fits the COX-2 Pocket
COX-2 has a larger active site than COX-1, with a secondary arginine residue (Arg513 in COX-2 vs. histidine in COX-1) that creates a side pocket. Rofecoxib's -SO2CH3 sulfonamide group extends into this pocket, forming a hydrogen bond with Arg513. This interaction stabilizes binding in COX-2 but causes steric clash in the narrower COX-1 pocket, reducing affinity by over 200-fold (IC50 COX-2: 0.2 μM; COX-2/COX-1 ratio: ~265).[1][3]
Role of the Furanone Ring and Aromatic Substituents
The five-membered γ-butyrolactone (furanone) ring positions the aryl groups optimally for hydrophobic interactions in COX-2's main channel. The 3-fluoro substitution on one phenyl ring enhances binding via van der Waals contacts, while the methylsulfonylphenyl locks into the side pocket. Without the sulfonamide, selectivity drops sharply, as seen in non-selective analogs.[2][4]
Comparisons with Other COX-2 Inhibitors
Unlike celecoxib's pyrazole-based sulfonamide, rofecoxib's furanone lacks a trifluoromethyl group but compensates with the rigid heterocycle for similar Arg120 hydrogen bonding (main site). Etoricoxib uses a pyridine scaffold but retains the sulfonamide pocket fit. Mutations like COX-2 V523I mimic COX-1 bulkiness, abolishing rofecoxib selectivity, confirming steric gating as primary.[3][5]
Crystal Structure Evidence
X-ray structures (PDB: 3NT1 for COX-2:rofecoxib) show the sulfonamide oxygen atoms H-bonding to Arg513 and Tyr355, with the furanone carbonyl interacting with Ser530. COX-1 models predict ~2 Å steric overlap, explaining poor binding.[2][4]
Sources
[1]: Nature Reviews Drug Discovery: COX-2 inhibitors
[2]: PDB: COX-2 rofecoxib complex
[3]: J. Med. Chem.: Selectivity mechanisms
[4]: Science: Structural basis of selectivity
[5]: PNAS: Mutant studies